Airtek (salmeterol, fluticasone propionate) aerosolum for inhalation 25 mcg/250 mcg/dose (120 doses)

Description

Pharmacodynamics.

Airtec contains salmeterol and fluticasone propionate, which have different mechanisms of action.

Salmeterol

Salmeterol is a selective agonist of b2-adrenoceptors of long (12 hours) action, which has a long side chain associated with the external domain of the receptor.

Salmeterol provides longer-lasting bronchodilation (at least 12 hours) than the recommended doses of traditional short-acting b2-adrenoceptor agonists.

Fluticasone propionate

Fluticasone propionate when used by inhalation in recommended doses exerts a pronounced glucocorticoid anti-inflammatory effect in the lungs, which leads to a decrease in clinical symptoms and the frequency of exacerbations of bronchial asthma without the appearance of adverse reactions observed with the systemic use of corticosteroids.

Indication

Airtek (salmeterol, fluticasone propionate) aerosolum  is intended for the treatment of bronchial asthma in patients who are shown to have combined therapy with long-acting β2-adrenomimetics and inhaled corticosteroids, namely:

• in case of insufficient control of the disease on the background of constant monotherapy with inhaled corticosteroids with periodic application of short-acting β2-adrenomimetics;
• in the case of adequate control of the disease on the background of therapy with inhaled corticosteroids and β2-adrenomimetics long-acting.

Airtek is not a drug for the elimination of acute symptoms that require the use of fast and short-acting bronchodilators. The patient should be advised to always carry a drug to relieve symptoms.

When the control of the symptoms of bronchial asthma is achieved, the dose of the drug should be gradually reduced. During dose reduction, regular monitoring of the patient is important. The lowest effective dose should be used.

Dosage and Administration

The drug is intended for inhalation use only.

Patients should be aware that Airtek must be used regularly, even during periods of absence of bronchial asthma attacks.

Patients should undergo regular medical examinations so that the dose selected for them remains optimally effective, which can only be changed by a doctor. The dose of the drug should be titrated to the minimum effective level, which provides control over the symptoms of the disease. If such effective control is achieved against the background of the minimally effective dose of the drug when it is used 2 times a day, the next step may be to transfer the patient to the use of one inhaled corticosteroid. As an alternative for the treatment of patients who need to use long-acting b2-agonists, the dose of Airtek can be reduced to 1 time per day if, in the opinion of the doctor, adequate control of the symptoms of the disease is maintained. If the patient has a history of nocturnal attacks of bronchial asthma, this single dose should be used at bedtime,

The amount of fluticasone propionate in the chosen form of Airtek should correspond to the severity of the disease. Note: Airtek in a dose of 25 mcg/50 mcg is not acceptable for the treatment of adults and children with severe bronchial asthma.

Recommended doses

Adults and children aged 12 years and older: 2 inhalations of 25 mcg salmeterol/50 mcg fluticasone propionate 2 times a day or 2 inhalations of 25 mcg salmeterol/125 mcg fluticasone propionate 2 times a day or 2 inhalations of 25 mcg salmeterol/250 mcg fluticasone propionate 2 times a day.

Children aged 4-12 years: 2 inhalations of 25 mcg of salmeterol and 50 mcg of fluticasone propionate 2 times a day. The maximum daily dose of fluticasone propionate is 100 mcg 2 times a day.